|Description||Pasireotide pamoate, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.|
|B0084-465329||5 mg||$598||In stock|
|Synonyms||Pasireotide; SOM230; SOM-203; SOM 203; Signifor|
Cortistatin 14 is an endogenous neuropeptide similar to somatostatin-14 in structure and function. It is mainly expressed in the cortex and hippocampus. It show...
FK 960 is a somatostatin receptor agonist and a 5-HT agonist activating both serotonin and somatostatin production as a cognitive enhancer. The phase II clinica...
Pasireotide L-aspartate salt
Pasireotide is a synthetic long-acting cyclic hexapeptide exhibits unique high-affinity binding to human somatostatin receptors.
Somatostatin is an endogenous peptide that inhibits the release of growth hormone, insulin and glucagon. Somatostatin also blocks voltage-dependent calcium chan...
L-803,087 trifluoroacetate is the trifluoroacetate salt of L-803,087, which is a selective and potent somatostatin sst4 receptor agonist often overexpressed in ...
L-817,818 is a selective and potent somatostatin sst5 receptor agonist with Ki value of 0.4 nM for cloned human sst5 receptors. It inhibits insulin release from...
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective and potent somatostatin sst2 receptor agonist with Ki value of 4nm. Its Ki values are 537, 3614, 2480 and 5017 ...
Octreotide acetate is a long-acting octapeptide with pharmacologic actions similars to the natural hormone somatostatin. It is a more potent inhibitor of growth...